LMO1 rs2168101: Understanding Neuroblastoma Susceptibility
The rs2168101 variant is a single nucleotide polymorphism located within the LMO1 gene, which has been identified as a susceptibility factor for neuroblastoma. Research suggests this variant may influence the expression of the LMO1 protein, which plays a role in the development of sympathetic nervous system cells.
What each genotype means
Increased neuroblastoma risk
This genotype contains the G allele, which is associated with higher LMO1 expression and an increased susceptibility to developing neuroblastoma. Research indicates that this variant disrupts a GATA transcription factor binding site, potentially promoting an adrenergic cell state that can contribute to tumor initiation.
The G allele is the major allele in many populations, making the GG genotype relatively common in individuals of European and East Asian ancestry.
Intermediate neuroblastoma risk
Carrying one copy of the T allele is associated with a reduced risk of neuroblastoma compared to the GG genotype. The T allele is thought to be protective by altering the regulatory environment of the LMO1 gene, which may limit the formation of high-risk adrenergic cell states.
This heterozygous genotype is frequently observed in populations where the T allele is present, occurring in approximately 30% of individuals in some European and East Asian cohorts.
Reduced neuroblastoma risk
This genotype is associated with the lowest risk of neuroblastoma susceptibility among the three possibilities. The TATA allele at this locus is linked to a mesenchymal cell state, which is considered lower risk at diagnosis compared to the adrenergic state associated with the G allele.
The T allele is common in European and East Asian populations but is rare or absent in African populations, making the TT genotype significantly less common in those groups.
What is rs2168101?
The variant rs2168101 is a single nucleotide polymorphism (SNP) located within the LMO1 gene on chromosome 11. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is situated within a super-enhancer region of the LMO1 gene. Super-enhancers are specialized clusters of regulatory elements that drive high levels of gene expression in specific cell types. By residing in this regulatory area, the rs2168101 variant is thought to alter how the cell controls the activity of the LMO1 gene. Because this region is evolutionarily conserved, changes here can have functional consequences on how transcription factors bind to DNA, potentially impacting the development of certain tissues during embryogenesis.
The Role of the LMO1 Gene
The LMO1 gene encodes a protein known as LIM domain only 1. This protein functions as a transcriptional cofactor, meaning it does not bind directly to DNA but instead interacts with other proteins to regulate the transcription of genes. LMO1 is particularly important in the development of the sympathetic nervous system, where it helps maintain the identity of adrenergic cells. In the context of cancer research, LMO1 is often described as an oncogene. When its expression is dysregulated, it can contribute to the formation and progression of neuroblastoma, a type of cancer that arises from immature nerve cells. By influencing the core regulatory circuitry of these cells, LMO1 helps determine whether a cell remains in a more differentiated state or adopts a more aggressive, tumor-promoting identity.
Research and Evidence Strength
The association between rs2168101 and neuroblastoma was first identified through genome-wide association studies (GWAS). Research has shown that the variant disrupts a GATA transcription factor binding site, which is critical for the normal regulation of LMO1. While the statistical association is robust across multiple studies, the evidence regarding its clinical utility remains limited. It is important to note that having a specific genotype at this locus does not mean an individual will develop neuroblastoma; rather, it indicates a difference in susceptibility. The biological mechanism is complex, involving the interplay between genetic predisposition and other factors that drive tumor initiation. Because neuroblastoma is a rare disease, the absolute risk for any individual remains very low, and this variant is only one piece of a much larger, multifactorial genetic puzzle.
Population Frequency
The rs2168101 variant is considered a common polymorphism, meaning it is found at varying frequencies across different global populations. Studies have examined this variant in diverse cohorts, including European and Asian populations, to understand its impact on disease risk. Because the frequency of the alleles can differ significantly by ancestry, the relative risk associated with the variant may also vary. Researchers often use these frequency differences to fine-map the region and identify the specific functional changes that contribute to disease susceptibility. While the variant is common, its presence in the general population is not inherently indicative of disease, as most individuals carrying the risk-associated allele will never develop neuroblastoma.
Interpreting Your Genetic Information
If you have received information about your rs2168101 genotype, it is essential to understand that this is a research-level finding rather than a diagnostic tool. Genetic variants associated with complex diseases like neuroblastoma provide insight into biological pathways but do not predict individual health outcomes. You cannot use this information to diagnose a condition or determine a personal risk level in a clinical sense. If you have concerns about family history or specific health risks, the most appropriate step is to consult with a board-certified genetic counselor or a medical professional. They can help place genetic findings into the context of your overall health and family history. Avoid making medical decisions based on raw genetic data, as these results require professional interpretation to be meaningful.
How common is this variant?
The rs2168101 variant is a common polymorphism observed across diverse global populations, with allele frequencies varying by ancestral background.
Frequently asked questions
Does having the G allele mean I will get neuroblastoma?
No. The rs2168101 variant is a susceptibility factor, not a direct cause of neuroblastoma. Most people who carry the G allele will never develop the disease.
What is a super-enhancer?
A super-enhancer is a large cluster of regulatory DNA elements that work together to drive high levels of gene expression. They are crucial for defining cell identity during development.
Can I use this information to change my diet or lifestyle?
There is no evidence that lifestyle or dietary changes can mitigate the risk associated with this specific genetic variant. This information is primarily used for scientific research into disease mechanisms.
Should I get my children tested for this variant?
Clinical testing for this variant is not standard practice for neuroblastoma screening. If you have concerns about your child's health, please speak with a pediatrician or a genetic specialist.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2168101?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29